US5586226A
(en)
*
|
1990-05-16 |
1996-12-17 |
Canon Kabushiki Kaisha |
Control method and device for a unicolor printer
|
US5912410A
(en)
*
|
1990-06-15 |
1999-06-15 |
Scios Inc. |
Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
|
AU652997B2
(en)
*
|
1991-01-21 |
1994-09-15 |
Elan Pharmaceuticals, Inc. |
Test and model for alzheimer's disease
|
ES2204899T3
(es)
*
|
1992-01-07 |
2004-05-01 |
Elan Pharmaceuticals, Inc. |
Modelos de animales transgenicos para la enfermedad de alzheimer.
|
US6610493B1
(en)
|
1993-06-17 |
2003-08-26 |
Brigham And Women's Hospital |
Screening compounds for the ability to alter the production of amyloid-β peptide
|
US6264915B1
(en)
|
1992-09-13 |
2001-07-24 |
The President And Fellows Of Harvard College |
Process for detecting potential carcinogens
|
US5436153A
(en)
*
|
1992-12-02 |
1995-07-25 |
Sprecher; Cindy A. |
Human amyloid protein precursor homolog and Kunitz-type inhibitor
|
WO1994012637A2
(en)
*
|
1992-12-02 |
1994-06-09 |
Zymogenetics, Inc. |
Novel human amyloid protein precursor homologue and kunitz-type inhibitors
|
DK0730643T3
(da)
|
1993-10-27 |
2001-05-14 |
Elan Pharm Inc |
Transgene dyr, som huser APP-allel med svensk mutation
|
JPH07132033A
(ja)
*
|
1993-11-12 |
1995-05-23 |
Hoechst Japan Ltd |
アルツハイマー病モデルトランスジェニック動物
|
CA2182311A1
(en)
|
1994-01-27 |
1995-08-03 |
Karen Hsiao |
Transgenic non-human mammals with progressive neurologic disease
|
US5877399A
(en)
|
1994-01-27 |
1999-03-02 |
Johns Hopkins University |
Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
|
FR2716460B1
(fr)
*
|
1994-02-21 |
2002-08-09 |
Rhone Poulenc Rorer Sa |
Modèle animal de la maladie d'Alzheimer, préparation et utilisations.
|
US6025183A
(en)
*
|
1994-02-28 |
2000-02-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Transgenic animal assay system for anti-cholinesterase substances
|
AU2635295A
(en)
*
|
1994-06-13 |
1996-01-05 |
Henry Ford Health System |
A novel neuronal-neonatal gene: neuronatin
|
EP0778886A4
(de)
*
|
1994-09-01 |
2001-05-02 |
|
Transgenes tier welches eine familiäre form vom menschlichen amyloiden vorläuferprotein exprimiert
|
US6114133A
(en)
*
|
1994-11-14 |
2000-09-05 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
|
US7427392B1
(en)
|
1994-11-14 |
2008-09-23 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
|
US6187992B1
(en)
|
1994-12-05 |
2001-02-13 |
Merck & Co., Inc. |
Transgenic mouse having a disrupted amyloid precursor protein gene
|
CA2206789A1
(en)
*
|
1994-12-05 |
1996-06-13 |
Merck & Co., Inc. |
Transgenic animal lacking native amyloid precursor protein
|
US5777194A
(en)
*
|
1995-04-26 |
1998-07-07 |
Cephalon, Inc. |
Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
|
US5777093A
(en)
*
|
1995-05-16 |
1998-07-07 |
Ramot-University Authority For Applied Research & Industrial Development Ltd. |
cDNAs associated with ataxia-telangiectasia
|
US5858661A
(en)
|
1995-05-16 |
1999-01-12 |
Ramot-University Authority For Applied Research And Industrial Development |
Ataxia-telangiectasia gene and its genomic organization
|
US5728807A
(en)
*
|
1995-05-16 |
1998-03-17 |
Ramot-University Authority For Applied Research And Industrial Development, Ltd. |
Mutated proteins associated with ataxia-telangiectasia
|
US6187991B1
(en)
|
1995-05-23 |
2001-02-13 |
Pfizer Inc |
Transgenic animal models for type II diabetes mellitus
|
WO1996040896A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Athena Neurosciences, Inc. |
Method for identifying alzheimer's disease therapeutics using transgenic animal models
|
AU6264996A
(en)
*
|
1995-06-07 |
1996-12-30 |
Athena Neurosciences, Inc. |
Method for identifying alzheimer's disease therapeutics usin g transgenic animal models
|
US6717031B2
(en)
*
|
1995-06-07 |
2004-04-06 |
Kate Dora Games |
Method for selecting a transgenic mouse model of alzheimer's disease
|
US5894078A
(en)
*
|
1996-02-26 |
1999-04-13 |
Advanced Bioconcept, Inc. |
Transgenic mouse expressing C-100 app
|
US6140309A
(en)
*
|
1996-03-12 |
2000-10-31 |
University Of South Florida |
Vasoactive effects and free radical generation by β-amyloid peptides
|
AU3640297A
(en)
*
|
1996-06-06 |
1998-01-05 |
University Of Washington |
Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
|
CA2259123C
(en)
|
1996-07-01 |
2003-10-21 |
Jim A. Wright |
Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
|
US20010016951A1
(en)
|
1996-07-24 |
2001-08-23 |
Bernd Sommer |
Transgenic animal model for alzheimer disease
|
WO1998003643A2
(en)
*
|
1996-07-22 |
1998-01-29 |
Smithkline Beecham Pharma Gmbh |
Transgenic animals with mutant human app or a4ct sequences
|
PT920495E
(pt)
*
|
1996-07-24 |
2008-08-18 |
Novartis Pharma Gmbh |
Modelo animal transgénico para doença de alzheimer
|
JP2000517185A
(ja)
|
1996-08-29 |
2000-12-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
新規なメタロプロテアーゼファミリーkuz
|
US6566089B1
(en)
*
|
1996-09-04 |
2003-05-20 |
Tularik Inc. |
Cell-based drug screens for regulators of gene expression
|
AU4867097A
(en)
*
|
1996-10-10 |
1998-05-05 |
Institut Pasteur |
Transgenic or mutated animal as model for a neuron deficit
|
US5898094A
(en)
*
|
1996-10-21 |
1999-04-27 |
University Of South Florida |
Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
|
US7973156B2
(en)
|
1997-08-21 |
2011-07-05 |
Quark Pharmaceuticals Inc. |
Hypoxia-regulated genes
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
JP4652566B2
(ja)
|
1998-01-12 |
2011-03-16 |
ロビン・エイ・フェルダー |
本態性高血圧症におけるgタンパク質関連変異体
|
AU3311699A
(en)
*
|
1998-02-25 |
1999-09-15 |
Board Of Regents Of The University And Community College System Of Nevada, The |
Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US6548261B1
(en)
|
1998-12-30 |
2003-04-15 |
Case Western Reserve University |
Alzheimer model for drug screening
|
EP1026251A3
(de)
*
|
1999-02-03 |
2000-09-06 |
Pfizer Products Inc. |
Transgene Tiere welche das menschliche p25 Gen exprimieren
|
AU4078900A
(en)
|
1999-04-06 |
2000-10-23 |
Harrington Arthritis Research Center |
Methods for tracking the progression of alzheimer's disease and identifying treatments using transgenic mice
|
WO2000071671A2
(en)
|
1999-05-26 |
2000-11-30 |
New York University |
New mutant genes in familial british dementia and familial danish dementia
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
US6787318B1
(en)
|
1999-06-01 |
2004-09-07 |
Roskamp Research Institute, Llc |
Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US6541244B1
(en)
*
|
1999-06-07 |
2003-04-01 |
Cedars-Sinai Medical Center |
Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
|
WO2000075324A2
(en)
|
1999-06-09 |
2000-12-14 |
Arch Development Corporation |
Recombinant prion-like genes and proteins and materials and methods comprising same
|
US6875582B1
(en)
|
1999-08-19 |
2005-04-05 |
Omniscience Pharmaceuticals, Inc. |
Methods and targets of antibiotic resistance
|
US6864355B1
(en)
|
2000-05-02 |
2005-03-08 |
Yale University |
Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
|
EP1240350A4
(de)
|
1999-12-23 |
2003-11-19 |
Millennium Pharm Inc |
P2y12 rezeptor
|
KR100828058B1
(ko)
|
2000-01-12 |
2008-05-09 |
예일 유니버시티 |
Nogo 수용체가 매개하는 축삭 성장의 차단
|
WO2001053323A2
(en)
|
2000-01-24 |
2001-07-26 |
Ramot University Authority For Applied Research & Industrial Development Ltd. |
Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
|
US6982361B1
(en)
*
|
2000-02-25 |
2006-01-03 |
The Regents Of The University Of California |
Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal
|
EP1265849B1
(de)
*
|
2000-03-23 |
2006-10-25 |
Elan Pharmaceuticals, Inc. |
Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
CA2405912A1
(en)
|
2000-04-12 |
2001-10-18 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US6846813B2
(en)
*
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
EP1666452A2
(de)
|
2000-06-30 |
2006-06-07 |
Elan Pharmaceuticals, Inc. |
Verbindungen zur Behandlung der Alzheimerischen Krankheit
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
PE20020276A1
(es)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
|
MXPA02012560A
(es)
|
2000-06-30 |
2003-05-14 |
Elan Pharm Inc |
Compuestos para tratar la enfermedad de alzheimer.
|
HUP0300810A2
(hu)
|
2000-07-20 |
2003-08-28 |
M.G.V.S. Ltd. |
Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
US20030082605A1
(en)
*
|
2000-09-06 |
2003-05-01 |
Hodge Timothy A. |
Genomic DNA detection method and system thereof
|
US20050266494A1
(en)
*
|
2000-09-06 |
2005-12-01 |
Hodge Timothy A |
System and method for computer network ordering of biological testing
|
US20050239125A1
(en)
*
|
2000-09-06 |
2005-10-27 |
Hodge Timothy A |
Methods for genotype screening
|
US20050272085A1
(en)
*
|
2000-09-06 |
2005-12-08 |
Hodge Timothy A |
Methods for forensic and congenic screening
|
EP1978110B1
(de)
*
|
2000-09-06 |
2010-05-26 |
Transnetyx, Inc. |
Computer-basiertes Verfahren und System zum Screenen von genomischer DNS
|
US20030087286A1
(en)
*
|
2000-09-06 |
2003-05-08 |
Hodge Timothy A. |
Isolation of eukaryotic genomic DNA using magnetically responsive solid functionalized particles
|
US7494817B2
(en)
*
|
2000-09-06 |
2009-02-24 |
Transnet Yx, Inc. |
Methods for genotype screening using magnetic particles
|
US6900367B2
(en)
*
|
2000-09-29 |
2005-05-31 |
Novartis |
Transgenic Drosophila melanogaster expressing a β42 in the eye
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
US20020170078A1
(en)
*
|
2001-03-08 |
2002-11-14 |
Isabelle Mansuy |
Calcineurin-related transgenic mammals, compositions and methods
|
US7081561B2
(en)
|
2001-03-16 |
2006-07-25 |
The Regents Of The University Of California |
Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
|
MXPA03011046A
(es)
*
|
2001-06-01 |
2004-06-25 |
Elan Pharm Inc |
Hidroxialquilaminas.
|
AU2002315131A1
(en)
|
2001-06-13 |
2002-12-23 |
Elan Pharmaceuticals, Inc. |
Aminediols as agents for the treatment of alzheimer's disease
|
WO2003002122A1
(en)
*
|
2001-06-27 |
2003-01-09 |
Elan Pharmaceuticals, Inc. |
Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
|
US20070213407A1
(en)
*
|
2001-06-29 |
2007-09-13 |
Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc |
Compounds to treat Alzheimer's disease
|
MXPA04000338A
(es)
*
|
2001-07-10 |
2004-07-23 |
Upjohn Co |
Diamindioles para tratamiento de enfermedad de alzheimer.
|
US7053109B2
(en)
*
|
2001-07-10 |
2006-05-30 |
Pharmacia & Upjohn Company |
Aminediols for the treatment of Alzheimer's disease
|
US7297553B2
(en)
*
|
2002-05-28 |
2007-11-20 |
Nanosphere, Inc. |
Method for attachment of silylated molecules to glass surfaces
|
MXPA04001153A
(es)
*
|
2001-08-31 |
2005-02-17 |
Neurochem Int Ltd |
Derivados de amidina para tratar la amiloidosis.
|
US20060014186A1
(en)
*
|
2001-09-04 |
2006-01-19 |
Hodge Timothy A |
Methods for genotype screening of a strain disposed on an adsorbent carrier
|
US7244755B2
(en)
|
2001-10-04 |
2007-07-17 |
Pharmacia & Upjohn Company |
Hydroxypropylamines
|
BR0214035A
(pt)
*
|
2001-11-08 |
2005-04-26 |
Elan Pharm Inc |
Composto
|
AU2002352811A1
(en)
*
|
2001-11-19 |
2003-06-10 |
Elan Pharmaceuticals, Inc. |
Amino diols useful in the treatment of alzheimer's disease
|
AU2002358947A1
(en)
|
2001-12-05 |
2003-06-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
|
ES2545090T3
(es)
|
2001-12-21 |
2015-09-08 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina y GCSF
|
US6992176B2
(en)
|
2002-02-13 |
2006-01-31 |
Technion Research & Development Foundation Ltd. |
Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
|
WO2003072041A2
(en)
*
|
2002-02-27 |
2003-09-04 |
Merck & Co., Inc. |
Assays to monitor amyloid precursor protein processing
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US7262208B2
(en)
*
|
2002-04-30 |
2007-08-28 |
Elan Pharmaceuticals, Inc. |
Hydroxypropyl amides for the treatment of Alzheimer's disease
|
UY27967A1
(es)
*
|
2002-09-10 |
2004-05-31 |
Pfizer |
Acetil 2-hindroxi-1,3-diaminoalcanos
|
KR20050056250A
(ko)
|
2002-10-18 |
2005-06-14 |
주식회사 엘지생명과학 |
암 관련 유전자 군
|
EP1565428A1
(de)
|
2002-11-27 |
2005-08-24 |
Elan Pharmaceuticals, Inc. |
Substituierte harnstoffe und carbamate
|
US7341847B2
(en)
*
|
2003-04-02 |
2008-03-11 |
Agency For Science, Technology And Research |
Promoter construct for gene expression in neuronal cells
|
PE20050420A1
(es)
*
|
2003-04-21 |
2005-06-13 |
Elan Pharm Inc |
Fenacilo 2-hidroxi-3-diaminoalcanos
|
MXPA05011150A
(es)
|
2003-04-21 |
2005-12-14 |
Elan Pharm Inc |
2-hidroxi-3-diaminoalcanos de benzamida.
|
IL155666A
(en)
*
|
2003-04-29 |
2013-12-31 |
Neurim Pharma 1991 |
Insomnia treatment
|
CA2525547C
(en)
|
2003-05-14 |
2012-07-03 |
Torreypines Therapeutics, Inc. |
Compounds and uses thereof in modulating amyloid beta
|
EP2361928B1
(de)
|
2003-05-19 |
2017-04-26 |
Prothena Biosciences Limited |
Verkürzte Alpha-Synuklein-Fragmente in der Lewy-Körper-Krankheit
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
TWI374893B
(en)
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US20060014790A1
(en)
*
|
2004-01-21 |
2006-01-19 |
Varghese John |
Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
|
US7262223B2
(en)
*
|
2004-01-23 |
2007-08-28 |
Neurochem (International) Limited |
Amidine derivatives for treating amyloidosis
|
JP2007528402A
(ja)
*
|
2004-03-09 |
2007-10-11 |
エラン ファーマシューティカルズ,インコーポレイテッド |
置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
|
US20050239832A1
(en)
*
|
2004-03-09 |
2005-10-27 |
Varghese John |
Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
|
JP2007528404A
(ja)
|
2004-03-09 |
2007-10-11 |
エラン ファーマシューティカルズ,インコーポレイテッド |
置換された尿素およびカルバメート、フェナシル−2−ヒドロキシ−3−ジアミノアルカン、ならびにベンズアミド−2−ヒドロキシ−3−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
|
CA2558034A1
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
SE0400707D0
(sv)
|
2004-03-22 |
2004-03-22 |
Bioarctic Neuroscience Ab |
Transgenic animal model
|
KR100574544B1
(ko)
*
|
2004-04-01 |
2006-04-27 |
주식회사 뉴로테크 |
돌연변이 βCTF99를 발현하는 알츠하이머병 유발형질전환 마우스
|
US7544855B2
(en)
*
|
2004-04-23 |
2009-06-09 |
Buck Institute |
Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
|
WO2005110422A2
(en)
*
|
2004-05-19 |
2005-11-24 |
Boehringer Ingelheim International Gmbh |
Treatment of diseases associated with altered level of amyloid beta peptides
|
JP4476050B2
(ja)
*
|
2004-06-30 |
2010-06-09 |
株式会社ニデック |
視野計
|
US7385085B2
(en)
*
|
2004-07-09 |
2008-06-10 |
Elan Pharmaceuticals, Inc. |
Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
|
JP2008505929A
(ja)
*
|
2004-07-09 |
2008-02-28 |
エラン ファーマシューティカルズ,インコーポレイテッド |
オキシム誘導体ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
|
US8436006B2
(en)
*
|
2004-08-06 |
2013-05-07 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8383637B2
(en)
*
|
2004-08-06 |
2013-02-26 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8426429B2
(en)
*
|
2004-08-06 |
2013-04-23 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
GB0419124D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Proteome Sciences Plc |
Methods and compositions relating to Alzheimer's disease
|
CA2577392A1
(en)
*
|
2004-08-27 |
2006-03-09 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
CA2590337C
(en)
|
2004-12-15 |
2017-07-11 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
US20090124993A1
(en)
|
2005-02-17 |
2009-05-14 |
Burkly Linda C |
Treating neurological disorders
|
EP1746092A1
(de)
|
2005-07-22 |
2007-01-24 |
Exonhit Therapeutics SA |
Verbindungen und Methoden zur Behandlung von Erkrankungen die in Verbindung mit beta-Amyloidpeptiden stehen
|
US20080293680A1
(en)
*
|
2005-08-03 |
2008-11-27 |
Stefan Peters |
Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II
|
JP2009504614A
(ja)
*
|
2005-08-11 |
2009-02-05 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アルツハイマー病の治療用化合物
|
EP1915339A1
(de)
*
|
2005-08-11 |
2008-04-30 |
Boehringer Ingelheim International GmbH |
Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
|
WO2007017509A1
(de)
*
|
2005-08-11 |
2007-02-15 |
Boehringer Ingelheim International Gmbh |
Verbindungen zur behandlung der alzheimer erkrankung
|
US20100168070A1
(en)
*
|
2005-08-11 |
2010-07-01 |
Niklas Heine |
Compounds for the treatment of alzheimer's disease
|
WO2007047305A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
|
CA2624904A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
|
JP2009525110A
(ja)
|
2006-01-31 |
2009-07-09 |
マルチ ジーン バスキュラー システムズ, インコーポレイテッド |
薬物溶出血管内プロテーゼおよび使用方法
|
US7932261B2
(en)
*
|
2006-02-06 |
2011-04-26 |
Janssen Pharmaceutica Nv |
Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
|
WO2007092846A2
(en)
*
|
2006-02-06 |
2007-08-16 |
Janssen Pharmaceutica N.V. |
2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
|
WO2007092854A2
(en)
*
|
2006-02-06 |
2007-08-16 |
Janssen Pharmaceutica N.V. |
2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
WO2009017467A1
(en)
|
2007-07-27 |
2009-02-05 |
Elan Pharma International Limited |
Treatment of amyloidogenic diseases
|
US9505823B2
(en)
*
|
2006-08-07 |
2016-11-29 |
TEV A Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
US8454948B2
(en)
|
2006-09-14 |
2013-06-04 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
EP2061515A4
(de)
|
2006-09-14 |
2013-01-30 |
Medgenics Medical Israel Ltd |
Heilmittelformulierungen mit langzeitwirkung
|
EA016568B1
(ru)
|
2006-10-12 |
2012-05-30 |
Беллус Хелс (Интернэшнл) Лимитед |
Способы, соединения, композиции и носители для доставки 3-амино-1-пропансульфоновой кислоты
|
PL381605A1
(pl)
|
2007-01-25 |
2008-08-04 |
Instytut Biologii Doświadczalnej Im. M. Nenckiego Polskiej Akadmii Nauk |
Transgeniczne zwierzę i sposób jego otrzymywania
|
WO2008112898A2
(en)
|
2007-03-13 |
2008-09-18 |
The Children's Hospital Of Philadelphia |
Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
|
WO2008152507A2
(en)
|
2007-03-16 |
2008-12-18 |
Multigene Vascular Systems, Inc. |
Compositions and methods for treating ophthalmic disorders
|
EP2144935A2
(de)
|
2007-03-29 |
2010-01-20 |
Technion Research & Development Foundation Ltd. |
Antikörper, methoden und kits zur diagnose und behandlung von melanomen
|
HUE030719T2
(en)
|
2007-04-09 |
2017-05-29 |
Univ Florida |
RAAV vector formulations and methods comprising tyrosine-modified capsid proteins for their use
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
US8222264B2
(en)
|
2007-07-06 |
2012-07-17 |
Boehringer Ingelheim International Gmbh |
Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
NZ586831A
(en)
*
|
2008-01-28 |
2012-02-24 |
Janssen Pharmaceutica Nv |
6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
|
US7786116B2
(en)
*
|
2008-01-29 |
2010-08-31 |
Janssen Pharmaceutica N.V. |
2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
|
US20110177502A1
(en)
|
2008-02-19 |
2011-07-21 |
Hakon Hakonarson |
Identification of pediatric onset inflammatory disease loci and methods of use thereof for the diagnosis and treatment of the same
|
EP2116260A1
(de)
*
|
2008-04-16 |
2009-11-11 |
Freie Universität Berlin |
Screening-Verfahren von geeigneten Wirkstoffen zur Vorbeugung und Behandlung von Alzheimer (AD)
|
AU2009246134B2
(en)
|
2008-05-16 |
2016-03-03 |
The Children's Hospital Of Philadelphia |
Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US20110023152A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of cognition related genes in animals
|
EP2499282B1
(de)
|
2009-11-09 |
2015-04-22 |
NeuroGenetic Pharmaceuticals, Inc. |
Gamma-sekretase-modulierende verbindungen, verfahren zu ihrer identifikation und verwendungen dafür
|
US9816108B2
(en)
|
2010-04-23 |
2017-11-14 |
University Of Florida Research Foundation, Inc. |
rAAV-guanylate cyclase compositions and methods for treating lebers congenital amaurosis-1 (LCA1)
|
WO2011159758A2
(en)
|
2010-06-15 |
2011-12-22 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
JP6250394B2
(ja)
|
2010-08-19 |
2017-12-20 |
バック・インスティテュート・フォー・リサーチ・オン・エイジング |
軽度の認知障害(mci)および関連障害の処置方法
|
AU2013235422B2
(en)
|
2012-03-19 |
2016-12-15 |
Buck Institute For Research On Aging |
APP specific BACE inhibitors (ASBIs) and uses thereof
|
EP3653609B1
(de)
|
2013-02-12 |
2024-04-03 |
Buck Institute for Research on Aging |
Hydantoine als modulatoren von bace-vermittelter app-verarbeitung
|
EP3060144A1
(de)
|
2013-10-24 |
2016-08-31 |
Medgenics Medical Israel, Ltd |
Mikroorganen zur verzögerten freisetzung eines therapeutischen polypeptids und verfahren zur verwendung davon
|
US10704098B2
(en)
|
2014-10-29 |
2020-07-07 |
The Children's Hospital Of Philadelphia |
Diagnosis and treatment of genetic alterations associated with eosinophilic esophagitis
|
EP3626832A3
(de)
|
2014-11-25 |
2020-05-13 |
The Brigham and Women's Hospital, Inc. |
Verfahren zur identifizierung und behandlung einer person mit einer prädisposition für eine kardiometabolische krankheit oder eine davon betroffene person
|
WO2016085876A1
(en)
|
2014-11-25 |
2016-06-02 |
The Broad Institute Inc. |
Clonal haematopoiesis
|
WO2017035017A1
(en)
|
2015-08-21 |
2017-03-02 |
The Children's Hospital Of Philadelphia |
Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
|
US11142505B2
(en)
|
2015-08-27 |
2021-10-12 |
The Regents Of The University Of California |
Compositions for APP-selective BACE inhibition and uses therefor
|
US20190134000A1
(en)
|
2016-05-12 |
2019-05-09 |
Buck Institute For Research On Aging |
Compounds to promote normal processing of app
|
AU2022211959A1
(en)
*
|
2021-01-28 |
2023-08-24 |
Abrain |
Gene therapy for treating neurodegenerative diseases
|